AiCuris is focused on developing innovative antiviral therapies specifically designed for immunocompromised patients, who are at a heightened risk of severe infections. Their flagship product, PREVYMIS® (letermovir), is a first-in-class antiviral agent that prevents cytomegalovirus (CMV) infections in high-risk transplant recipients. This drug has received approvals in multiple countries, including a recent approval in Japan for use in adult solid organ transplant patients. Additionally, AiCuris is advancing its pipeline with pritelivir, a novel helicase-primase inhibitor currently in Phase 3 trials aimed at treating acyclovir-resistant herpes simplex virus (HSV) infections, and AIC468, an antisense oligonucleotide targeting BK virus (BKV) infections, which is set to enter Phase 1 trials.

The company is also collaborating with the German Center for Infection Research (DZIF) to discover new antiviral agents and treatment approaches for immunocompromised patients. This partnership aims to leverage the expertise of both organizations to identify novel therapeutic targets and enhance the development of effective antiviral solutions. AiCuris is committed to addressing the urgent medical needs of over a billion individuals worldwide who are immunocompromised, ensuring they have access to precise and effective treatment options for potentially life-threatening infections.

Germany

AiCuris (from 'Anti-infective Cures'​) is a pharmaceutical company focused on the discovery, research and development of novel antiviral agents for the treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients.

Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris has a broad and innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

AiCuris

Company Details